The therapeutic implications of renin-angiotensin system blockade in diabetic retinopathy

Current Pharmaceutical Biotechnology

Volumn 12, Issue 3, 2011, Pages 392-395

  Jeganathan, V Swetha E ^a  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

Blood pressure; Diabetes mellitus; Diabetic retinopathy; Direct; Dream; Euclid; Navigator; Renin angiotensin system

Indexed keywords

CANDESARTAN; ENALAPRIL; GLICLAZIDE; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; LISINOPRIL; LOSARTAN; NATEGLINIDE; RAMIPRIL; ROSIGLITAZONE; VALSARTAN;

ARTICLE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG DOSE INCREASE; HEART FAILURE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DIABETIC RETINOPATHY; HUMANS; HYPERGLYCEMIA; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 79551676689     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111794480615     Document Type: Article

References (38)

1. Chrysant, S. G. Current status of dual Renin Angiotensin aldosterone system blockade for the treatment of cardiovascular diseases. Am. J. Cardiol., 2010, 105(6), 849-852.
2. Laight, D.W. Therapeutic inhibition of the renin angiotensin aldosterone system. Exp. Opin. Ther. Pat., 2009, 19(6),753-759.
3. Fletcher, E.L.; Phipps, J. A.; Ward, M. M.; Vessey, K. A.; wilkinson-Berka, J. L. The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Prog. Retin. Eye Res., 2010, 29(4),284-311.
4. Milenkovic, V. M.; Brockmann, M.; Meyer, C.; Desch, M.; Schweda, F.; Kurtz, A.; Todorov, V.T.; Strauss, O. Regulation of the renin expression in the retinal pigment epithelium by systemic stimuli. Am. J. Physiol. Renal. Physiol., 2010, 299(2), F396-F403.
5. Ruggenenti, P.; Cravedi, P.; Remuzzi, G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat. Rev. Nephrol., 2010, 6(6), 319-330.
6. Loriga, G. Direct Renin inhibition: promising treatment in renoprotection? Recent Pat. Cardiovasc. Drug Discov., 2010, 5(2), 113-119.
7. Nguyen G. The (pro)renin receptor in health and disease. Ann. Med., 2010, 42(1), 13-18.
8. Triggle, C.R. The early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetes. Drugs Today (Barc), 2007, 43(11), 815-826.
9. Crawford, T. N.; Alfaro, D. V; Kerrison, J.B.; Jablon, E. P. Diabetic retinopathy and angiogenesis. Curr. Diabetes Rev., 2009, 5(1), 8-13.
10. Wong, W. T.; Tian, X. Y.; Xu, A.; Ng, C. F.; Lee, H. K.; Chen, Z.Y. Angiotensin II type 1 eceptor-dependent oxidative stress mediates endothelial dysfunction in type 2 diabetic mice. Antioxid. Redox. Signal., 2010, 13(6), 757-768.
11. Wilkinson-Berka, J. L.; Miller, A.G.; Fletcher, E. L. Prorenin and the (pro)renin receptor: do they have a pathogenic role in the retina? Front Biosci., (Elite Ed). 2010, 2, 1054-1064.
12. Silva, K. C.; Rosales, M. A.; de Faria, J. B.; de Faria, J. M. Reduction of inducible nitric oxide synthase via angiotensin receptor blocker prevents the oxidative retinal damage in diabetic hypertensive rats. Curr. Eye Res., 2010, 35(6), 519-528.
13. Kim, J. H.; Yu, Y. S.; Cho, C. S.; Kim, K. W. Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy. J. Cereb. Blood Flow Metab., 2009, 29(3), 621-628.
14. Grossman, E.; Messerli, F. H. Hypertension and diabetes. Adv. Cardiol., 2008, 45, 82-106.
15. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ, 1998, 317(7160), 703-713.
16. Naviglio, S.; Pirozzi, F. Renin-Angiotensin system blockade for diabetic nephropathy prevention. Am. J. Cardiol., 2010, 105(10), 1505.
17. Wright, A. D.; Dodson, P. M. Diabetic retinopathy and blockade of the renin-angiotensin system: new data from the DIRECT study programme. Eye, (Lond) 2010, 24(1),1-6.
18. Ketelhut, R.; Bramlage, P. Candesartan cilexetil/ hydrochloro-thiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study. Clin. Drug Investig., 2010, 30(5), 301-311.
19. Mehlsen, J.; Jeppesen, P.; Erlandsen, M.; Poulsen, P. L.; Bek, T. Lack of effect of short-term treatment with Amlodipine and Lisinopril on retinal autoregulation in normotensive patients with type 1 diabetes and mild diabetic retinopathy. Acta Ophthalmol.,2010, [Epub ahead of print]
20. Luhtala, S.; Vaajanen, A.; Oksala, O.; Valjakka, J.; Vapaatalo, H. Activities of angiotensin converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues. J. Ocul. Pharmacol. Ther., 2009, 25(1), 23-28.
21. Cerbone, A. M.; Macarone-Palmieri, N.; Saldalamacchia, G.; Coppola, A.; Di Minno, G.; Rivellese, A. A. Diabetes, vascular complications and antiplatelet therapy: open problems. Acta Diabetol., 2009, 46(4), 253-261.
22. Sjolie, A. K. Prospects for angiotensin receptor blockers in diabeticretinopathy. Diabetes Res. Clin. Pract., 2007, 76 (Suppl 1), S31-S39.
23. Chaturvedi, N.; Sjolie, A. K.; Stephenson, J. M.; Abrahamian, H.; Keipes, M.; Castellarin.; Rogulja-Pepeonik, Z.; Fuller, J. H. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB controlled trial of lisinopril in insulin-dependent diabetes mellitus. Lancet, 1998, 351(9095), 28-31.
24. Strain, W. D.; Chaturvedi, N. The renin-angiotensin-aldosterone system and the eye in diabetes. J. Renin Angiotensin Aldosterone Syst., 2002, 3(4),243-246.
25. Chaturvedi, N.; Porta, M.; Klein, R.; Orchard, T.; Fuller, J.; Parving, H.H.; Bilous, R.; Sjølie, A. K. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet, 2008, 372(9647), 1394-1402.
26. Mitchell, P.; Wong, T.Y. DIRECT new treatments for diabetic retinopathy. Lancet, 2008, 372(9647), 1361-1363.
27. Klein, R.; Moss, S.E.; Sinaiko, A.R.; Zinman, B.; Gardiner, R.; Suissa, S.; Donnelly, S. M.; Kramer, M. S.; Goodyer, P.; Strand, T.; Mauer, M. The relation of ambulatory blood pressure and pulse rate to retinopathy in type 1 diabetes mellitus: the renin-angiotensin system study. Ophthalmology, 2006, 113(12), 2231-2236.
28. Steckelings, U. M.; Rompe, F.; Kaschina, E.; Unger, T. The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundam. Clin. Pharmacol., 2009, 23(6), 693-703.
29. Mauer, M.; Zinman, B.; Gardiner, R.; Drummond, K. N.; Suissa, S.; Donnelly, S. M.; Strand, T. D.; Kramer, M. S.; Klein, R.; Sinai-ko, A. R. ACE-I and ARBs in early diabetic nephropathy. J. Renin. Angiotensin Aldosterone Syst., 2002, 3(4), 262-269.
30. Beulens, J. W.; Patel, A.; Vingerling, J. R.; Cruickshank, J. K.; Hughes, A. D.; Stanton, A. Lu, J.; Mc, G.; Thom, S. A.; Grobbee, D. E.; Stolk, R. P. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia, 2009, 52(10), 2027-2036.
31. Stolk, R.P.; van Schooneveld, M. J.; Cruickshank, J. K.; Hughes, A. D.; Stanton, A.; Lu, J.; Retinal vascular lesions in patients of Caucasian and Asian origin with type 2 diabetes: baseline results from the ADVANCE Retinal Measurements (AdRem) study. Diabetes Care, 2008, 31(4), 708-713.
32. Lonn, E. M.; Gerstein, H. C.; Sheridan, P.; Smith, S.; Diaz, R.; Mohan, V.; Bosch, J.; Yusuf, S.; Dagenais, G. R. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). J. Am. Coll. Cardiol., 2009, 53(22), 2028-2035.
33. Dagenais, G. R.; Gerstein, H. C.; Holman, R.; Budaj, A.; Escalante, A.; Hedner, T.; Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care, 2008, 31(5), 1007-1014.
34. Hanley, A. J.; Zinman, B.; Sheridan, P.; Yusuf, S.; Gerstein, H. C. Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. Diabetes Care, 2010, 33(3), 608-613.
35. Scheen, A. J. [NAVIGATOR: A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide]. Rev. Med. Liege, 2010, 65(4), 217-223.
36. Cleland, J. G.; Coletta, AP, Buga L, Ahmed D, Clark AL. Clinical trials update from the American College of Cardiology meeting 2010: DOSE, ASPIRE, CONNECT, STICH, STOP-AF, CABANA, RACE II, EVEREST II, ACCORD, and NAVIGATOR. Eur. J. Heart Fail, 2010, 12(6), 623-629.
37. Califf, R. M.; Boolell, M.; Haffner, S.M.; Bethel, M. A.; McMurray, J.; Duggal, A.; Holman, R. R. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am. Heart J., 2008, 156(4), 623-632.
38. Komajda, M.; Wimart, M. C. Angiotensin converting enzyme inhibition: from viper to patient. Heart, 2000, 84 (Suppl 1): i11-i14.